Alterations in Cancer-related Genes Associated with Grading of We
Pancreatic Disorders & Therapy

Pancreatic Disorders & Therapy
Open Access

ISSN: 2165-7092

+44 7868 792050

Research Article - (2017) Volume 7, Issue 3

Alterations in Cancer-related Genes Associated with Grading of Well Differentiated Pancreatic Neuroendocrine Neoplasms

Yudai Yokota1, Mitsuharu Fukasawa1, Shinichi Takano1*, Hiroko Shindo1, Ei Takahashi1, Makoto Kadokura1, Kunio Mochizuki2, Shinya Maekawa1, Jun Itakura3, Hideki Fujii3, Tadashi Sato1 and Nobuyuki Enomoto1
1Department of Internal Medicine, University of Yamanashi 1110, Shimokato, Chuo, Yamanashi 409-3898, Japan
2Department of Pathology, University of Yamanashi 1110, Shimokato, Chuo, Yamanashi 409-3898, Japan
3Department of Surgery, University of Yamanashi 1110, Shimokato, Chuo, Yamanashi 409-3898, Japan
*Corresponding Author: Shinichi Takano, Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi 409-3898, Japan, Tel: +81-55-273-9584, Fax: +81-55-273-6748 Email:


Objectives: Although recent advances in next-generation sequencing (NGS) have revealed some genetic alterations in various tumors, including pancreatic neuroendocrine tumors (PanNETs), their clinical significance is not fully understood. To investigate the clinical significance of gene alteration in PanNETs, we performed genetic analysis of well differentiated PanNETs using NGS.

Methods: Twenty-nine resected primary PanNET tissue samples and three samples of metastatic liver tissues, obtained from 29 PanNET patients, were analyzed. DNA was extracted from laser-captured formalin-fixed paraffinembedded tissues, and 50 cancer-associated genes, including approximately 2,800 hotspots, were amplified by multiplex PCR. Amplified libraries were sequenced using NGS, and the results were analyzed in conjunction with respective clinicopathological features.

Results: Among 50 investigated genes, somatic mutations were observed in four of 29 PanNET cases. We identified APC mutations in three cases, PTEN in two, and VHL and STK11 in one. The identified mutations were observed only in NET G2 tumors. All liver metastases contained at least one mutation, such as PTEN or TP53, which was not observed in the primary tumor.

Conclusion: The cancer-related gene mutations observed in PanNETs were associated with G2 grade tumors. The mutations were more frequent in PanNET liver metastasis than in the primary tumors. Our analysis of liver metastasis cases suggested that cancer-related gene mutations might raise the tumor grade and promote liver metastasis. Further studies of associations between genetic alterations and clinicopathological features should help in the cancer diagnosis and prediction of therapeutic effects of molecular-target drugs.


Keywords: Pancreatic neuroendocrine tumor; WHO 2010 grading classification; Mutation; Next-generation sequencing


Pancreatic neuroendocrine tumors (PanNETs) are rare tumors that comprise 1–2% of pancreatic neoplasms [1], with an annual incidence of 0.32/100,000 in the United States [2] and 1.27/100,000 in Japan [3]. Most of these tumors are more indolent than other epithelial malignant tumors; however, they can be aggressive, with the 5-year survival of 27-79% [2,4]. Surgery is the only curative treatment for PanNETs in the absence of metastasis to other organs. Although there is evidence to support hepatectomy for resectable liver metastases [5], the effectiveness of resection of the primary tumor in the presence of unresectable liver metastases remains controversial [6,7]. In such cases, other therapies might be used, including somatostatin analogs, peptide-receptor radionuclide therapy, liver-directed chemoembolization, radiofrequency ablation of hepatic metastases, and chemotherapy [8]. Recently, molecular-targeted agents such as sunitinib or everolimus have been used as a first-line therapy for patients with advanced and Grade 1 (G1) or G2 tumor (World Health Organization (WHO) classification 2010) [9,10].

Although prognosis evaluation for patients with these tumors is difficult, recent studies have established TNM staging and grading as independent prognostic factors of PanNETs [11,12]. The European Neuroendocrine Tumors Society has proposed a 3-tier grading classification system based on the mitotic rate and/or the Ki-67 proliferative index [13]. The subsequently published classifications of the Union for International Cancer Control and WHO were based on the classification by European Neuroendocrine Tumors Society [14]. Recent advances in endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) have enabled preoperative grading of PanNETs [15]. These classifications are important to determine the indications for chemotherapy and molecular-targeted agents [9,10].

Majority of PanNETs occur as sporadic, isolated tumors, although some PanNETs are a part of complex familial endocrine cancer syndromes such as multiple endocrine neoplasm type 1 (MEN-1), MEN-2, von Hippel–Lindau disease (VHL), neurofibromatosis type 1, and tuberous sclerosis complex [8]. Recent whole-exome sequencing identified several frequently mutations in sporadic well-differentiated PanNETs, including in MEN1, DAXX, ATRX, PTEN, TSC2, and PIK3CA [16]. Some of these genes are tumor suppressor genes but the role of these genetic alterations in tumorigenesis and progression of PanNETs and their clinical significance remain unclear.

Recent advances in next-generation sequencing (NGS) technology allow a rapid and inexpensive identification of actionable mutations in multiple genes. DNA isolated from formalin-fixed paraffin embedded (FFPE) clinical tissue specimens is often of poor quality and available in very limited quantities; however, sufficient sequencing libraries can be obtained by multiplex PCR with short amplicons [17]. In this study, we analyzed genetic alterations in the FFPE samples of resected well differentiated PanNETs (NET G1/G2) using NGS technology to clarify the clinicopathological significance of genetic mutations in PanNETs.

Subjects and Methods


We used tumor tissue samples from 29 patients whose PanNETs were surgically resected between 1990 and 2013 at Yamanashi University Hospital. Clinical information, including age, sex, symptoms, tumor size, localization at presentation, hereditary status, pathology, TNM stage, surgical procedure, and follow-up time, were retrospectively collected from the medical records. All tumors were histologically reviewed and classified into three grades according to the WHO 2010 classification [14]. This study was approved by the Human Ethics Review Committee of Yamanashi University Hospital.

DNA extraction

Tumor tissue and adjacent normal pancreatic tissue were separately laser-microdissected from the same 8-μm-thick sections of FFPE blocks using an Applied Biosystems ArcturusXT microdissection instrument (Life Technologies, Foster City, CA). DNA was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Milan, Italy) following the manufacturer’s instructions. Extracted DNA was quantitated by measuring the optical density at A260-nm and A280- nm wavelengths.

Multiplex PCR of targeted genes and deep sequencing

Amplification of targeted genes and deep sequencing were performed as described previously [18]. In brief, 10-ng aliquots of extracted DNA were amplified using multiplex PCR methods with the ready-made premixed primer kit (Ion AmpliSeq Cancer Hotspot Panel v2, Life Technologies). Approximately 2,800 mutations were targeted in the following 50 cancer-associated genes in the COSMIC database [19]: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, JAK2, JAK3, IDH2, KDR/VEGFR2, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, and VHL. The primer kit contains 207 primer pairs with a relatively short amplicon length to improve the PCR performance impaired by the fragmentation of DNA extracted from FFPE. The PCR products were checked using a high-sensitivity DNA assay on the Agilent 2100 Bioanalyzer on-chip (Agilent Technologies, Santa Clara, CA, USA).

The PCR products were further amplified by emulsion PCR using OneTouch OT2 system (Life Technologies) and then sequenced on the Ion Torrent PGM sequencer (Life Technologies) loaded with a 318 Chip. Torrent Suite Software v.4.0 (Life Technologies) was used to align reads to the hg19 reference genome and generate run metrics, including total read counts and quality. Variant Caller v.4.0 (Life Technologies) was used to identify variants. When the variants were detected in both tumor tissue and normal pancreatic tissue, they were considered germ-line variants. Variants identified only in tumor tissue and identical to the COSMIC database were considered tumor-specific somatic mutations, and the cut-off value of variant frequency per read depth was set at 8% to avoid erroneous variant calls [17].


Immunohistochemistry was performed as reported previously [20]. In brief, deparaffinized sections of formalin-fixed tissue of 2-μm thicknesses were stained with primary antibodies specific for Ki-67 (1:100 dilutions; cat, M7240; Dako, Carpinteria, CA, USA). Antigen retrieval was achieved by boiling the tissue sections in Target Retrieval Solution (Dako) in an autoclave unit for 20 min at 120°C before incubation with anti-Ki-67. Envision kit/HRP (AEC) (cat. K1491; Dako) was used as the secondary antibody, and diaminobenzidine was used as the chromogen. All sections were counterstained with hematoxylin. Following the WHO 2010 recommendations [14], the Ki-67 index was calculated by counting 2000 cells in areas of the strongest nuclear labeling to establish the grade of each PanNET.

Statistical Analysis

Because the tumor grade has prognostic significance for PanNET, its association with genomic alterations and clinicopathological variables was assessed. Continuous variables were compared using Mann– Whitney U-test. Categorical variables were compared using χ2 or Fisher’s exact test as appropriate. A p-value of <0.05 was considered statistically significant.


Patient characteristics

A summary of the clinicopathological features of the 29 PanNETs is shown in Table 1. There were five functioning tumors, including three insulinomas and two gastrinomas. We observed two patients with inherited PanNET syndromes and both had MEN1. One of them had a pancreatic gastrinoma, and it was diagnosed as MEN1 because of the familial history of hyperparathyroidism and pituitary microadenoma.

Characteristic Value
Age (years), median (range) 61 (33–81)
Female 13
Male 16
Symptomatic 4
Abdominal pain 1
Hypoglycemia 3
Asymptomatic 25
Yes 5
No 24
Size (mm), median (range) 12 (2–80)
Body or tail 18
Head 11
Tumor feature
Cystic component 5
Encapsulated 6
Hereditary status
Sporadic 27
MEN-1 2
WHO Grade
NET G1 18
NET G2 11
UICC Stage
I 20
II 5
IV 3
Surgical treatment
Enucleation 3
Segmental resection 7
DP 9
PD 10
Follow-up (days), median (range) 799 (30–5117)
Alive 23
Dead 2
NA 4
DP, distal pancreatectomy; PD, pancreatoduodenectomy; NA, not available

Table 1: Baseline characteristics of the 29 tumors.

The other patient had multiple non-functioning PanNETs with liver metastasis, and the cancer was diagnosed as MEN1 because of the multiple lesions and hyperparathyroidism. Among the 29 patients, 18 (62.0%) had NET G1 and 11 (37.9%) had NET G2. There were no cases of neuroendocrine carcinoma or mixed adenoneuroendocrine carcinoma. Three patients had distant metastases, two of whom had metastasis in the liver and the third had both liver and nodal involvement. During the mean follow-up period of 799 days (range, 30–5,177 days), two patients died because of liver metastasis progression.

Deep sequence analysis of 50 cancer-related genes in resected tissues of primary PanNET

The mean DNA concentration of 25.8 ng/μl was obtained from a microdissected sample of approximately 7 mm2. The average of 364,904 mapped sequence reads for each sample and 1,280 reads for each amplicon were achieved. The average of 19.4 variants was detected in each sample, of which 3.4 variants existed in the COSMIC database. We identified four mutated genes in four (13.8%) patients (Figure 1). APC was mutated in three patients (10.3%), PTEN in two (6.9%), STK11 in one (3.4%), and VHL in one patient (3.4%). One patient had mutations in three genes (APC, PTEN, and STK11), another patient in two (APC and VHL), and the remaining two patients had one mutation each, in APC and VHL. Mutations in APC, PTEN, and STK11 were frameshift mutations and the mutation in VHL was a missense. All identified mutations were observed in patients with NET G2, and there were no mutations in patients with NET G1 (Table 2).


Figure 1: Percentage of cases with mutations in each of the 50 cancer-related genes. APC mutations were detected in 10.3% (three of 29 cases), PTEN mutations in 6.9% (two of 29 cases), both STK11 and VHL mutations in 3.4% (one of 29 cases).

  APC PTEN STK11 VHL      
  Amino acid VF Amino acid VF Amino acid VF Amino acid VF Tumor size    
Case substitution (%) substitution (%) substitution (%) substitution (%) (mm) Grade Stage
1 p.N1455fs*18 17.6 p.T321fs*23 30.6 p.P281fs*6 28.6 WT   19 G2 I
2 p.T1556fs*9 18.1 WT   WT   WT   35 G2 III
3 p.T1556fs*9 18.1 WT   WT   p.P86S 86.7 80 G2 IV
4 WT   p.T321fs*23 33.3 WT   WT   10 G2 I
5 WT   WT   WT   WT   10 G2 I
6 WT   WT   WT   WT   30 G2 IV
7 WT   WT   WT   WT   13 G2 I
8 WT   WT   WT   WT   9 G2 I
9 WT   WT   WT   WT   18 G2 I
10 WT   WT   WT   WT   23 G2 II
11 WT   WT   WT   WT   9 G2 I
12 WT   WT   WT   WT   40 G1 II
13 WT   WT   WT   WT   12 G1 I
14 WT   WT   WT   WT   13 G1 I
15 WT   WT   WT   WT   9 G1 I
16 WT   WT   WT   WT   12 G1 I
17 WT   WT   WT   WT   15 G1 II
18 WT   WT   WT   WT   12 G1 I
19 WT   WT   WT   WT   30 G1 II
20 WT   WT   WT   WT   3 G1 I
21 WT   WT   WT   WT   12 G1 II
22 WT   WT   WT   WT   12 G1 I
23 WT   WT   WT   WT   14 G1 I
24 WT   WT   WT   WT   2 G1 I
25 WT   WT   WT   WT   8 G1 I
26 WT   WT   WT   WT   15 G1 I
27 WT   WT   WT   WT   5 G1 I
28 WT   WT   WT   WT   10 G1 IV
29 WT   WT   WT   WT   8 G1 I
PanNET, pancreatic neuroendocrine tumor; VF, variant frequency; WT, wild type; fs, frame shift

Table 2: Mutations and clinicopathological data of PanNET cases.

Association of clinical and mutational variables with tumor grades

The mutation status and other clinicopathological variables were statistically assessed for their association with the tumor grade (Table 3). Among these variables, only the presence of mutations in 50 cancer-related genes was significantly associated with NET G2.

Clinicopathological factors NET G1 NET G2 P value
Age 63(48–81) 56(33–79) 0.393†
Sex Female 9 4 0.702*
Male 9 7  
Symptoms Symptomatic 3 1 0.566*
Asymptomatic 15 10  
Functioning Yes 3 2 0.917*
No 15 9  
Size   12(2–40) 13(9–80) 0.131†
Location Body or tail 12 6 0.696*
Head 6 5  
Cystic lesion Yes 3 2 0.917*
No 15 9  
Multiplicity Solitary 15 11 0.268*
Multicentric 3 0  
Lymphatic or blood
vessel invasion
Present 6 4 0.868*
Absent 12 7  
Mutations Present 0 4 0.014*
No mutations 18 7  
Stage I­­­­­–III 17 9 0.539*
IV 1 2  
PanNET, pancreatic neuroendocrine tumor
†Mann-Whitney U test; *Fisher’s exact test

Table 3: Correlation of tumor grade with clinicopathological data of PanNET.

Deep sequence analysis of 50 cancer-related genes in patients with primary PanNET and liver metastasis.

Among the 29 patients, three underwent not only surgical resections of primary pancreatic tumors but also simultaneous liver resection of synchronous metastasis. We also analyzed these resected liver specimens for somatic mutations of the 50 cancer-related genes. Among the three liver specimens, one had a newly developed mutation in TP53 besides the same mutation in VHL as the primary pancreatic tumor, and the others had a newly developed mutation in PTEN or TP53. Two of three cases had an advanced tumor grade with a newly developed gene mutation (Table 4).

  Primary Liver Metastasis
Case Grade Mutations VF (%) Grade Mutations VF (%)
3 G2 APC 18.1 G3 TP53 96.9
VHL 86.7 VHL 69.6
6 G2 WT   G2 TP53 68.7
28 G1 WT   G2 PTEN 65.3
WT: wild type; VF: variant frequency

Table 4: Mutations in the APC, VHL, and PTEN genes in patients with primary tumor and liver metastasis.


Our understanding of the biological basis of PanNET and its clinical associations remains limited. We performed a comprehensive deep sequencing analysis of 50 cancer-related genes in resected well differentiated PanNET (NET G1/G2) tissues using NGS and analyzed the associations with their clinical variables. We identified mutations in APC (10.3%), PTEN (6.9%), VHL (3.4%), and STK11 (3.4%) exclusively in PanNET G2 tumors, which carry a higher malignancy grade than PanNET G1. The results of the pair analysis for primary tissue and metastasis to the liver showed that the liver metastatic tissues had a higher mutation frequency and were of the higher grade than the primary PanNET.

Recent advances in NGS have enabled rapid, cost-effective, and comprehensive gene sequencing, resulting in the accumulation of evidence of gene alterations in various tumors, including PanNET [16,17,21]. Two recent studies have reported comprehensive genetic analyses of PanNET cases. Jiao et al. have conducted whole-exome sequencing of PanNET and identified mutations in MEN1 (44.1%), DAXX (25%), ATRX (17.6%), PTEN (7.3%), TSC (28.8%), and PIK3CA (1.4%) [16]. Young et al. have conducted NGS of 287 cancerrelated genes for various neoplasms (including PanNET) and identified the STK11 mutation [22]. The previously reported genes MEN1, DAXX, ATRX, and TSC were not assessed in our study, because they were not included in the multiplex PCR kit that we used. APC, PTEN, VHL, and STK11, in which we detected mutations in G2 but not in G1 tumors, are all tumor suppressor genes. A reduction in the tumor suppression function might have raised the histological grade of PanNETs. APC is a member of the Wnt signaling cascade and protects β-catenin from dephosphorylation by PP2A, thereby enhancing β- catenin phosphorylation and degradation. The loss of APC function stabilizes β-catenin and promotes its nuclear translocation, resulting in cell cycle progression, and enhances the expression of oncogenes [23-25]. There are only two reports investigating APC mutation in PanNET; one study examined a clinical sample with no mutation and the other examined two PanNET cell lines with APC mutations [22,26]. However, there are seven reports that examined β-catenin abnormality, and only six (3.1%) of 191 reported cases have either nuclear accumulation of β-catenin or β-catenin mutations [27-33]. PTEN and STK11 suppress the activation of the mTOR signaling pathway, and loss-of-function mutations for these genes result in the activation of this signal [34,35]. Recently, the mTOR pathway inhibitors have been shown to increase progression-free survival in advanced cases of PanNETs [9]; the mutational status of the mTOR pathway genes may predict the clinical response to mTOR inhibitors. Our data showed a mutation of either PTEN or STK11 in two of 29 cases (6.9%), the rate equivalent to that observed in the previous exome-sequence study [16]. VHL is a tumor suppressor gene in VHL disease in which PanNETs are observed in 12% to 17% of cases [36]. Mutation of VHL causes disruption of the interaction between the transcription factor HIF and VHL protein, leading to constitutive HIF activation and expression of HIF targets, affecting many cellular processes such as angiogenesis and cell metabolism [37,38]. One case of a VHL mutation in our study could be considered sporadic because the mutation was observed only in the tumor and not in a non-tumor sample.

Our analysis of liver metastasis cases suggests that cancer-related gene mutations may raise the tumor grade and promote liver metastasis. Liver metastasis has been reported in more than 50% of cases of PanNET [39], and the elevation of the Ki-67 index in primary tumors increases the probability of metastasis [40]. The Ki-67 index or tumor grade is higher for liver metastatic sites than primary sites [40,41]; however, there are no reports examining the mutational status of both primary and metastatic sites. In our analysis of three PanNET patients with liver metastasis, all three metastatic site had a newly developed mutation, which was not detected in the primary site, and two of three cases had an advanced grade in the metastatic site than in the primary site. This suggests that the elevation of the tumor grade and presence of a mutation might promote liver metastasis.

In the future, it might be possible to assess the tumor grade and predict therapeutic effects of molecular-target drugs more precisely. Recent advances in the EUS-FNA technique make it easy to obtain tumor tissues preoperatively or before chemotherapy administration [42,43]. The concordance rate of the Ki-67 index of PanNETs between resected specimens and EUS-FNA specimens is reported to be 74% [15]. In addition to the elevation of the Ki-67 index, the cancer-related gene mutation in EUS-FNA specimens might indicate increased chances of being a G2 tumor. It might be possible to predict therapeutic effects of molecular-targeted agents such as mTOR inhibitors using EUS-FNA specimens for the detection of mutations in the mTOR pathway, such as PTEN, STK11, and PIK3CA. Our analysis and another study detected mutations in the mTOR pathway in 6.9– 15.0% of PanNET cases [16]. Moreover, multiple gene analysis of clinically obtained specimens such as EUS-FNA and pancreatic juice samples is already possible [18,22].

For limitations, the number of patients included in our study may be small for adequate statistical analysis, and our study observed mutations of cancer-related genes only in patients with G2 tumors and demonstrated a high incidence of mutations in metastatic liver sites. However, there were no patients with more malignant G3 tumors and only three patients with liver metastasis were observed in our study. Some of the genes whose alterations have been previously reported were not analyzed here because they were not included in the readymade panel that we used. Comprehensive gene analysis in such malignant tumors would give us more clinically important findings.

In conclusion, cancer-related gene mutations were observed in G2 PanNETs using NGS analysis of resected well differentiated PanNET (NET G1/G2) samples. Such mutations and a higher grade of cancer were observed in some of the liver metastatic sites, whereas no mutations were detected in the respective primary sites. These findings may pave the way to improvements in cancer diagnosis, prognosis, and treatment, especially in combination with some new techniques such as EUS-FNA.


We thank Asuka Kanayama and Takako Ohmori for their valuable technical assistance and Hiroko Amemiya and Eriko Takamuro for their secretarial assistance. The authors would like to thank Enago ( for the English language review. This study was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (25860527 and 26670380; and grants from the Foundation for Advancement of International Science ( members.pdf). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have declared no competing interests.


  1. Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas: best practice and research. Clin Gastroenterol 19: 753-781.
  2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, et al. (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072.
  3. Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, et al. (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in japan: a nationwide survey analysis. J Gastroenterol 50: 58-64.
  4. Hauso O, Gustafsson BI, Kidd M, Drozdov I, Waldum HL, et al. (2008) Neuroendocrine tumor epidemiology: contrasting norway and north america. Cancer 10: 2655-2664.
  5. Mayo SC, Jong MC, Pulitano C, Clary BM, Reddy SK, et al. (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17: 3129-3136.
  6. Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, et al. (2009) Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 41: 49-55.
  7. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, et al. (2009) Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 115: 741-751.
  8. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, et al. (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61: 6-32.
  9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.
  10. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, et al. (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513.
  11. Rindi G, Falconi M, Klersy C, Albarello L, BoninsegnaL, et al. (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764-77.
  12. Scarpa A, Mantovani W, Capelli P, BeghelliS, BoninsegnaL, et al. (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23: 824-833.
  13. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395-401.
  14. Bosman FT, Carneiro F, Hruban R (2010) WHO classification of tumors of the digestive system. IARC: 322-326.
  15. Hasegawa T, Yamao K, Hijioka S, Bhatia V, Mizuno N, et al. (2014) Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endo 46: 32-38.
  16. Jiao Y, Shi C, Edil BH, Wilde RF, Klimstra DS, et al. (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331: 1199-1203.
  17. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, et al. (2012) Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn 15: 171-176.
  18. Takano S, Fukasawa M, Maekawa S, Kadokura M, Miura M, et al. (2014) Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PloS one 9.
  19. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39: 945-950.
  20. Matsui A, Yamaguchi T, Maekawa S, Miyazaki C, Takano S, et al. (2009) DICKKOPF-4 and -2 genes are upregulated in human colorectal cancer. Cancer Sci 100: 1923-1930.
  21. Jones S, Zhang X, Parsons DW, Leary RJ, Angenendt P, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Sci 321: 1801-1806.
  22. Young G, Wang K, He J, Otto G, Hawryluk M, et al. (2013) Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 121: 688-694.
  23. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398.
  24. Krausova M, Korinek V (2014) Wnt signaling in adult intestinal stem cells and cancer. Cell Signal 26: 507-509.
  25. White BD, Chien AJ, Dawson DW (2012) Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterol 142: 219-232.
  26. Kim JT, Li J, Jang ER, GulhatiP, Rychahou PG, et al. (2013) Deregulation of Wnt/beta-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis 34: 953-961.
  27. Gerdes B, Ramaswamy A, Simon B, Pietsch T, Bastian D, et al. (1999) Analysis of beta-catenin gene mutations in pancreatic tumors. Digestion 60: 544-548.
  28. Hervieu V, Lepinasse F, Gouysse G, GuillaudO, Barel C, et al. (2006) Expression of beta-catenin in gastroenteropancreatic endocrine tumours: a study of 229 cases. J Clin Pathol 59: 1300-1304.
  29. Kubota Y, Kawakami H, Natsuizaka M, Kawakubo K, Marukawa K, et al. (2015) CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing. J Gastroenterol 50: 203-210.
  30. Liu BA, Li ZM, Su ZS, She XL (2010) Pathological differential diagnosis of solid-pseudopapillary neoplasm and endocrine tumors of the pancreas. World J Gastroenterol 16: 1025-1030.
  31. Semba S, Kusumi R, Moriya T, Sasano H (2000) Nuclear accumulation of B-catenin in human endocrine tumors: association with Ki-67 (MIB-1) proliferative activity. Endocr Pathol 11: 243-250.
  32. Su MC, Wang CC, Chen CC, Hu RH, Wang TH, et al. (2006) Nuclear translocation of beta-catenin protein but absence of beta-catenin and APC mutation in gastrointestinal carcinoid tumor. Ann Surg Oncol 13: 1604-1609.
  33. Takahashi Y, Hiraoka N, Onozato K, Shibata T, Kosuge T, et al. (2006) Solid-pseudopapillary neoplasms of the pancreas in men and women: do they differ? Virchows Arch 448: 561-569.
  34. Tee AR, Blenis J (2005) mTOR, translational control and human disease. Semin Cell Dev Biol 16: 29-37.
  35. Zhang S, Yu D (2010) PI(3)king apart PTEN's role in cancer. Clin Cancer Res 16: 4325-4330.
  36. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, et al. (2007) Clinical, genetic and radiographic analysis of 108 patients with von hippel-lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142: 814-818.
  37. Richard S, Graff J, Lindau J, Resche F (2004) Von Hippel-Lindau disease. Lancet 363: 1231-1234.
  38. Speisky D, Duces A, Bieche I, Rebours V, Hammel P, et al. (2012) Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. Clin Cancer Res 18: 2838-2849.
  39. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, et al. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190: 432-445.
  40. Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, et al. (2014) Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg 38: 1353-1361.
  41. Zen Y, Heaton N (2013) Elevated Ki-67 labeling index in 'synchronous liver metastases' of well differentiated enteropancreatic neuroendocrine tumor. Pathol Int 63: 532-538.
  42. Ogura T, Yamao K, Sawaki A, Mizuno N, Hara K, et al. (2012) Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. Gastrointest Endosc 75: 769-774.
  43. Wang X, Gao J, Ren Y, Gu J, Du Y, et al. (2011) Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. American J Gastroenterol 106: 2104-2111.
Citation: Yokota Y, Fukasawa M, Takano S, Shindo H, Takahashi E, et al. (2017) Alterations in Cancer-related Genes Associated with Grading of Well Differentiated Pancreatic Neuroendocrine Neoplasms. Pancreat Disord Ther 7:189.

Copyright: © 2017 Yokota Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.